0001209191-20-012195.txt : 20200224
0001209191-20-012195.hdr.sgml : 20200224
20200224183808
ACCESSION NUMBER: 0001209191-20-012195
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200224
FILED AS OF DATE: 20200224
DATE AS OF CHANGE: 20200224
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Domzalski David
CENTRAL INDEX KEY: 0001727794
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 20646384
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-24
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001727794
Domzalski David
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLTZMAN STREET
REHOVOT
L3
7670402
ISRAEL
1
1
0
0
CEO
Ordinary Shares
2020-02-24
4
A
0
103248
0.00
A
319323
D
Options
4.03
2020-02-24
4
A
0
240912
0.00
A
2030-02-24
Ordinary Shares
240912
240912
D
This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024.
Each option represents a contingent right to purchase one ordinary share of the issuer.
The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024.
/s/ Mutya Harsch as attorney-in-fact
2020-02-24